Skip to main content

Table 1 Baseline Participant Characteristics, Overall and by Drug Therapy

From: Examining systemic steroid use in older inflammatory bowel disease patients using hurdle models: a cohort study

  Full cohort (n = 1682) Ever systemic steroid users (n = 726)a Ever nonbiologic users (n = 85)a
Sociodemographicsb n % n % n %
Age Mean (SD)c   79 (8)   78 (7)e   75 (7)e
 Female 1136 68 494 68 50 59
 Caucasian 1474 88 654 90d 80 94
 Region       
 Northeast 444 26 182 25 19 22
 Southeast 459 27 208 29 24 28
 Midwest 417 25 189 26 28 33
 Rocky Mountain 34 2 12 2 <11g <11g
 Southwest 163 10 96 10 <11g <11g
 Pacific (incl HI, AK, PR)h 165 10 68 9 <11g <11g
 Urban/Suburban 1266 76 516 72e 61 72
 Medicaid coverage 547 33 219 30 21 25
Clinicalb n % n % n %
 Polypharmacy (>5 drugs) 1290 81 602 85e 69 83
 Charlson Index Mean (SD)   4 (3)   4 (3)   4 (2)
 Primary managing provider type       
 Primary Care Provider 769 46 320 44.4 38 44.7
 Gastroenterologist 19 1 <11g <11g <11g <11g
 Other specialists 868 52 393 55 44 52
 antiTNF 37 2 26 4e 18 21e
 Aminosalicylates 374 22 215 30e 38 45e
 Locally administered steroids 12 1 <11g <11d,g <11g <11g
 Antidiarrheals 209 12 111 15e 14 17
 >1 endoscopy 452 27 201 28 25 29
 IBD surgery 106 6 41 6 <11g <11g
 Hospitalizations Mean (SD)   2 (2)   2 (2)e   2 (2)
 ED visits Mean (SD)   1 (2)   1 (2)e   1 (2)
  1. aBivariate analyses is the comparison of Steroid Use to NonUse; Nonbiologic Use to Nonuse; bBaseline characteristics were ascertained during 12 months prior to study inclusion; cSD = standard deviation d p < .05, e p < .01, f p < .001; gCell sizes are too small to include variable in regression model & requires cell suppression
  2. hHI = Hawaii, AK = Alaska, PR = Puerto Rico